Literature DB >> 27580684

Current best practice for disease activity assessment in IBD.

Alissa J Walsh1, Robert V Bryant2,3, Simon P L Travis1.   

Abstract

Therapeutic advances in the management of IBD have led to a paradigm shift in the assessment of IBD disease activity. Beyond clinical remission, objective assessment of inflammation is now critical to guiding subsequent therapy as part of a 'treat to target' strategy. Multiple domains of disease activity assessment in IBD exist, each of which has its merits, although none are perfect. The aim of this Review is to comprehensively evaluate measures of disease activity in both ulcerative colitis and Crohn's disease, including clinical, endoscopic, histological and radiological assessment tools, as well as the use of biomarkers and quality of life evaluation. A subjective appraisal of the best indices for use in clinical practice is provided, based on index validation, responsiveness and experience in clinical trials, international specialist opinion, and practicality and suitability for use in clinical practice. This Review aims to enable the reader to gain confidence in IBD disease activity assessment and to give ready access to the necessary tools.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27580684     DOI： 10.1038/nrgastro.2016.128

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  144 in total

1.  A classification of fistula-in-ano.

Authors:  A G Parks; P H Gordon; J D Hardcastle
Journal:  Br J Surg       Date:  1976-01       Impact factor: 6.939

2.  Reliability and initial validation of the ulcerative colitis endoscopic index of severity.

Authors:  Simon P L Travis; Dan Schnell; Piotr Krzeski; Maria T Abreu; Douglas G Altman; Jean-Frédéric Colombel; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Philippe R Marteau; Walter Reinisch; Bruce E Sands; Bruce R Yacyshyn; Patrick Schnell; Christian A Bernhardt; Jean-Yves Mary; William J Sandborn
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

3.  Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

Authors:  L S Kiss; T Szamosi; T Molnar; P Miheller; L Lakatos; A Vincze; K Palatka; Z Barta; B Gasztonyi; A Salamon; G Horvath; G T Tóth; K Farkas; J Banai; Z Tulassay; F Nagy; M Szenes; G Veres; B D Lovasz; Z Vegh; P A Golovics; M Szathmari; M Papp; P L Lakatos
Journal:  Aliment Pharmacol Ther       Date:  2011-08-24       Impact factor: 8.171

Review 4.  Mucosal healing in inflammatory bowel diseases: a systematic review.

Authors:  Markus F Neurath; Simon P L Travis
Journal:  Gut       Date:  2012-07-27       Impact factor: 23.059

5.  Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.

Authors:  Erik Mooiweer; Mirjam Severs; Marguerite E I Schipper; Herma H Fidder; Peter D Siersema; Robert J F Laheij; Bas Oldenburg
Journal:  J Crohns Colitis       Date:  2014-11-26       Impact factor: 9.071

6.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

7.  Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohn's disease.

Authors:  Vincenzo Migaleddu; Antonio M Scanu; Emilio Quaia; Paolo Cossu Rocca; Maria Pina Dore; Domenico Scanu; Lorenza Azzali; Giuseppe Virgilio
Journal:  Gastroenterology       Date:  2009-05-05       Impact factor: 22.682

8.  Factors associated with short- and long-term outcomes of therapy for Crohn's disease.

Authors:  Walter Reinisch; Jean-Frederic Colombel; William J Sandborn; Gerassimos J Mantzaris; Asher Kornbluth; Omoniyi J Adedokun; Michael Miller; Kezhen L Tang; Paul Rutgeerts; Freddy Cornillie
Journal:  Clin Gastroenterol Hepatol       Date:  2014-09-19       Impact factor: 11.382

9.  Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group.

Authors:  E J Irvine
Journal:  J Clin Gastroenterol       Date:  1995-01       Impact factor: 3.062

10.  Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.

Authors:  Simon P L Travis; Silvio Danese; Limas Kupcinskas; Olga Alexeeva; Geert D'Haens; Peter R Gibson; Luigi Moro; Richard Jones; E David Ballard; Johan Masure; Matteo Rossini; William J Sandborn
Journal:  Gut       Date:  2013-02-22       Impact factor: 23.059
View more
  56 in total

Review 1.  Factors that Influence Treatment and Non-treatment Decision Making Among Individuals with Inflammatory Bowel Disease: An Integrative Review.

Authors:  Kendra J Kamp; Kelly Brittain
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

Review 2.  Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?

Authors:  Rish K Pai; Karel Geboes
Journal:  Virchows Arch       Date:  2017-05-30       Impact factor: 4.064

Review 3.  Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review.

Authors:  Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey
Journal:  Qual Life Res       Date:  2017-08-28       Impact factor: 4.147

4.  The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application.

Authors:  Kathryn A Sexton; John R Walker; Laura E Targownik; Lesley A Graff; Clove Haviva; Brooke E Beatie; Sarah K Petty; Matthew T Bernstein; Harminder Singh; Norine Miller; Charles N Bernstein
Journal:  Inflamm Bowel Dis       Date:  2019-07-17       Impact factor: 5.325

5.  Crohn's disease active inflammation assessment with iodine density from dual-energy CT enterography: comparison with endoscopy and conventional interpretation.

Authors:  Bari Dane; Amelia Kernizan; Thomas O'Donnell; Robert Petrocelli; Wendy Rabbenou; Sumona Bhattacharya; Shannon Chang; Alec Megibow
Journal:  Abdom Radiol (NY)       Date:  2022-07-14

6.  Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer.

Authors:  Masayoshi Kobayashi; Nagahide Matsubara; Yutaka Nakachi; Yasushi Okazaki; Motoi Uchino; Hiroki Ikeuchi; Jihyng Song; Kei Kimura; Michiko Yasuhara; Akihito Babaya; Tomoki Yamano; Masataka Ikeda; Hiroki Nishikawa; Ikuo Matsuda; Seiichi Hirota; Naohiro Tomita
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

7.  A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease.

Authors:  William J Sandborn; Maria T Abreu; Marla C Dubinsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-05

8.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Authors:  Remo Panaccione; A Hillary Steinhart; Brian Bressler; Reena Khanna; John K Marshall; Laura Targownik; Waqqas Afif; Alain Bitton; Mark Borgaonkar; Usha Chauhan; Brendan Halloran; Jennifer Jones; Erin Kennedy; Grigorios I Leontiadis; Edward V Loftus; Jonathan Meddings; Paul Moayyedi; Sanjay Murthy; Sophie Plamondon; Greg Rosenfeld; David Schwartz; Cynthia H Seow; Chadwick Williams; Charles N Bernstein
Journal:  J Can Assoc Gastroenterol       Date:  2018-07-10

9.  Clinical effects of ursodeoxycholic acid on patients with ulcerative colitis may improve via the regulation of IL-23-IL-17 axis and the changes of the proportion of intestinal microflora.

Authors:  Zhengjun Wang; Jinhua Chen; Zhiping Chen; Longke Xie; Wen Wang
Journal:  Saudi J Gastroenterol       Date:  2021 May-Jun       Impact factor: 2.485

10.  Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.

Authors:  Marla C Dubinsky; Marco DiBonaventura; Haiyun Fan; Andrew G Bushmakin; Joseph C Cappelleri; Eric Maller; Andrew J Thorpe; Leonardo Salese; Julian Panés
Journal:  Inflamm Bowel Dis       Date:  2021-06-15       Impact factor: 5.325
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.